Parvinder Singh Hyare discloses 6.65% stake in Galera Therapeutics
Parvinder Singh Hyare reported beneficial ownership of 13,521,921 shares of common stock of Galera Therapeutics, representing 6.65% of the class, following a mandatory conversion of Series B Non-Voting Convertible Preferred Stock on May 15, 2026. Hyare, an executive officer or director, is party to a stockholder support agreement executed April 14, 2026, committing to vote in favor of the proposed merger with Obsidian Therapeutics and related transactions.
Key facts
- Parvinder Singh Hyare acquired 13,521,921 shares of common stock via mandatory conversion on May 15, 2026
- Beneficial ownership: 13,521,921 shares (6.65% of class)
- Series B Preferred Stock conversion ratio: 1,000 shares of common stock per share of preferred stock
- Stockholder support agreement dated April 14, 2026 with signatories holding 51.1% of outstanding capital stock
- Agreement and Plan of Merger with Obsidian Therapeutics executed April 14, 2026
- Nova Merger Agreement closed December 30, 2024; Hyare received 13,521.292 Series B Preferred shares at exchange ratio of 177.9117
Why it matters
Hyare's 6.65% stake, combined with his executive/director status and support agreement covering 51.1% of shares, positions him as a significant insider backer of the pending Obsidian Therapeutics merger transaction.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from SCHEDULE 13D filed 2026-06-11. Not investment advice. View the source filing on SEC.gov →